Company Registration No. 03432550 (England and Wales)
NSF HEALTH SCIENCES LTD.
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
NSF HEALTH SCIENCES LTD.
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 8
NSF HEALTH SCIENCES LTD.
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
4
-
0
2,607
Current assets
Debtors
5
1,962,073
1,929,525
Cash at bank and in hand
5,390,342
4,700,841
7,352,415
6,630,366
Creditors: amounts falling due within one year
6
(1,068,446)
(1,779,977)
Net current assets
6,283,969
4,850,389
Net assets
6,283,969
4,852,996
Capital and reserves
Called up share capital
7
2
2
Profit and loss reserves
6,283,967
4,852,994
Total equity
6,283,969
4,852,996

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 5 September 2025 and are signed on its behalf by:
L Tackett
Director
Company registration number 03432550 (England and Wales)
NSF HEALTH SCIENCES LTD.
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 January 2023
2
2,898,192
2,898,194
Year ended 31 December 2023:
Profit and total comprehensive income
-
1,954,802
1,954,802
Balance at 31 December 2023
2
4,852,994
4,852,996
Year ended 31 December 2024:
Profit and total comprehensive income
-
1,430,973
1,430,973
Balance at 31 December 2024
2
6,283,967
6,283,969
NSF HEALTH SCIENCES LTD.
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
1
Accounting policies
Company information

NSF Health Sciences Ltd. is a private company limited by shares incorporated in England and Wales. The registered office is Hanborough Business Park, Long Hanborough, Oxfordshire, United Kingdom, OX29 8SJ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover relates to training courses, consultancy services and medical device training. Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer once the service/ course/ training is delivered. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
5 years straight line
Computers
4 years straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

NSF HEALTH SCIENCES LTD.
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, amounts from fellow group companies, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

NSF HEALTH SCIENCES LTD.
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 5 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

Group relief

The company is part of a tax group with other group entities for corporation tax purposes. Group relief is used to manage the overall tax position of the group. Consideration is earned or paid for this group relief equivalent to the tax charge or credit transferred. These are disclosed as part of the total taxation charge.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.13
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

NSF HEALTH SCIENCES LTD.
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Bad debt provision

Having taken into consideration the historic and current levels of bad debts, the director considers it appropriate to have a specific bad debt provision in place. The director's assessment of the necessity and adequacy of the bad debt provision takes into consideration the latest available information regarding the recoverability of the relevant amounts and the circumstances of the customers.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
21
22
4
Tangible fixed assets
Fixtures and fittings
Computers
Total
£
£
£
Cost
At 1 January 2024
22,752
45,147
67,899
Disposals
(22,752)
(43,251)
(66,003)
At 31 December 2024
-
0
1,896
1,896
Depreciation and impairment
At 1 January 2024
20,750
44,542
65,292
Depreciation charged in the year
1,979
605
2,584
Eliminated in respect of disposals
(22,729)
(43,251)
(65,980)
At 31 December 2024
-
0
1,896
1,896
Carrying amount
At 31 December 2024
-
0
-
0
-
0
At 31 December 2023
2,002
605
2,607
NSF HEALTH SCIENCES LTD.
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
1,392,046
1,175,388
Corporation tax recoverable
174,645
162,877
Amounts owed by group undertakings
357,934
553,754
Other debtors
4,664
-
0
Prepayments and accrued income
27,298
32,020
1,956,587
1,924,039
Deferred tax asset
5,486
5,486
1,962,073
1,929,525
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
95,705
245,611
Amounts owed to group undertakings
68,885
515,024
Taxation and social security
152,824
130,675
Other creditors
751,032
888,667
1,068,446
1,779,977
7
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
2
2
2
2
8
Financial commitments, guarantees and contingent liabilities

The company is party to a group VAT registration and is therefore jointly and severally liable for the total amounts due to HM Revenue and Customs by all group companies included within that registration. At 31 December 2024, £687k (2023: £546k) was due and payable by NSF Safety and Quality UK Limited.

9
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
Total commitments
-
0
136,608
NSF HEALTH SCIENCES LTD.
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
10
Related party transactions

The company has taken advantage of the exemptions provided by FRS 102 Section 33, not to disclose transactions and outstanding balances with other companies of the NSF International Group which are directly or indirectly wholly owned by NSF International.

11
Parent company

The immediate parent undertaking of the company is NSF International UK Limited, whose registered address is: Hanborough Business Park, Long Hanborough, Oxfordshire, OX29 8SJ, United Kingdom.

The smallest and largest group of companies within which the company belongs and for which consolidated financial statements are available is that headed by NSF International, the ultimate controlling parent and the ultimate controlling party. NSF International is a not for profit corporation chartered under the laws of the state of Michigan, USA. Consolidated financial statements may be obtained from its registered address: NSF International, 789 North Dixboro Road, Ann Arbor, MI 48105, USA.

12
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

Senior Statutory Auditor:
Nikolaos Ioannidis
Statutory Auditor:
Shaw Gibbs (Audit) Limited
Date of audit report:
8 September 2025
2024-12-312024-01-01falsefalsefalse08 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityL TackettD Lonza034325502024-01-012024-12-31034325502024-12-31034325502023-12-3103432550core:FurnitureFittings2024-12-3103432550core:ComputerEquipment2024-12-3103432550core:FurnitureFittings2023-12-3103432550core:ComputerEquipment2023-12-3103432550core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3103432550core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3103432550core:CurrentFinancialInstruments2024-12-3103432550core:CurrentFinancialInstruments2023-12-3103432550core:ShareCapital2024-12-3103432550core:ShareCapital2023-12-3103432550core:RetainedEarningsAccumulatedLosses2024-12-3103432550core:RetainedEarningsAccumulatedLosses2023-12-3103432550core:ShareCapital2022-12-3103432550core:RetainedEarningsAccumulatedLosses2022-12-3103432550core:ShareCapitalOrdinaryShareClass12024-12-3103432550core:ShareCapitalOrdinaryShareClass12023-12-3103432550bus:Director12024-01-012024-12-3103432550core:RetainedEarningsAccumulatedLosses2023-01-012023-12-31034325502023-01-012023-12-3103432550core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3103432550core:FurnitureFittings2024-01-012024-12-3103432550core:ComputerEquipment2024-01-012024-12-3103432550core:FurnitureFittings2023-12-3103432550core:ComputerEquipment2023-12-31034325502023-12-3103432550bus:OrdinaryShareClass12024-01-012024-12-3103432550bus:OrdinaryShareClass12024-12-3103432550bus:OrdinaryShareClass12023-12-3103432550bus:PrivateLimitedCompanyLtd2024-01-012024-12-3103432550bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3103432550bus:FRS1022024-01-012024-12-3103432550bus:Audited2024-01-012024-12-3103432550bus:Director22024-01-012024-12-3103432550bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP